MK-2206

Generic Name: MK-2206

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₁N_₅O

CAS Number: 1032349-93-1

Unique Ingredient Identifier: 51HZG6MP1K

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 2

Withdrawn

Conditions: Recurrent Adult Primary Liver Cancer
Adenocarcinoma of the Gallbladder
Adult Primary Cholangiocellular Carcinoma
Stage II Gallbladder Cancer
Stage IIIB Gallbladder Cancer
Stage IVA Gallbladder Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Recurrent Extrahepatic Bile Duct Cancer
Stage IIIA Gallbladder Cancer
Stage IVB Gallbladder Cancer

Interventions: Drug: selumetinib
Drug: Akt inhibitor MK2206
Other: laboratory biomarker analysis
Other: pharmacogenomic studies
Procedure: quality-of-life assessment

First Posted Date: 2013-05-21

Last Posted Date: 2014-09-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01859182

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Rectal Signet Ring Cell Adenocarcinoma
Recurrent Colon Carcinoma
Recurrent Rectal Carcinoma
Rectal Mucinous Adenocarcinoma
Stage IIIC Colon Cancer
Colon Mucinous Adenocarcinoma
Colon Signet Ring Cell Adenocarcinoma
Stage IIIA Colon Cancer
Stage IIIA Rectal Cancer
Stage IVA Colon Cancer

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2013-03-01

Last Posted Date: 2019-09-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01802320

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Unresectable Pancreatic Carcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: Akt Inhibitor MK2206
Drug: Dinaciclib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2013-02-04

Last Posted Date: 2017-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT01783171

Locations: 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 2 locations

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Phase 2

Terminated

Conditions: Estrogen Receptor Positive
Stage IIA Breast Cancer
Stage IIIB Breast Cancer
HER2/Neu Negative
Stage IIB Breast Cancer
Recurrent Breast Carcinoma
Stage IIIC Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: Akt Inhibitor MK2206
Drug: Anastrozole
Drug: Goserelin Acetate
Other: Laboratory Biomarker Analysis
Procedure: Neoadjuvant Therapy
Other: Pharmacological Study
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2013-01-25

Last Posted Date: 2018-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01776008

Locations: 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 5 locations

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1

Terminated

Conditions: Adenocarcinoma of the Gastroesophageal Junction
HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Recurrent Esophageal Cancer
Recurrent Gastric Cancer
Stage IIIC Breast Cancer
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer
Stage IV Breast Cancer

Interventions: Drug: Akt inhibitor MK2206
Biological: trastuzumab
Drug: lapatinib ditosylate
Other: laboratory biomarker analysis

First Posted Date: 2012-10-12

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT01705340

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Pancreatic Acinar Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer

Interventions: Drug: Akt Inhibitor MK2206
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Selumetinib

First Posted Date: 2012-08-07

Last Posted Date: 2016-03-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 137

Registration Number: NCT01658943

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente-Riverside, Riverside, California, United States
🇺🇸
Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States

and more 530 locations

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

Phase 2

Completed

Conditions: Salivary Gland Adenoid Cystic Carcinoma
Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Stage IVC Major Salivary Gland Cancer AJCC v7
Recurrent Oral Cavity Adenoid Cystic Carcinoma
Stage IVB Major Salivary Gland Cancer AJCC v7
Stage IVA Major Salivary Gland Cancer AJCC v7
Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Recurrent Salivary Gland Carcinoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-05-24

Last Posted Date: 2019-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01604772

Locations: 🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Upper Valley Medical Center, Troy, Ohio, United States

and more 48 locations

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2

Terminated

Conditions: Recurrent Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions: Drug: Akt inhibitor MK2206
Drug: selumetinib
Other: laboratory biomarker analysis

First Posted Date: 2012-01-27

Last Posted Date: 2014-06-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT01519427

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

and more 1 locations

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2011-11-29

Last Posted Date: 2017-09-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01481129

Locations: 🇫🇷
Hopitaux de Paris, Vellefaux, Paris, France
🇫🇷
Institut Bergonie Cancer Center, Bordeaux, France
🇫🇷
Henri Mondor University-Hospital Center, Creteil, France

and more 6 locations

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Stage III Cutaneous Melanoma AJCC v7
Stage III Renal Cell Cancer AJCC v7
Stage IV Renal Cell Cancer AJCC v7
Stage III Prostate Cancer AJCC v7
Stage IV Prostate Cancer AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Drug: Akt Inhibitor MK2206
Drug: Hydroxychloroquine

First Posted Date: 2011-11-28

Last Posted Date: 2024-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT01480154

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy